Literature DB >> 10416588

Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines.

F Henry1, O Boisteau, L Bretaudeau, B Lieubeau, K Meflah, M Grégoire.   

Abstract

We have reported recently that treatments combining injections of apoptotic bodies from tumor cells and interleukin 2 led to tumor regression and induced specific protection. In the present study, we show that tumor-bearing rats were cured with an 80% success rate by injection of antigen-presenting cells (APCs) that had phagocytosed apoptotic bodies derived from poorly immunogenic tumor cells, whereas phagocytic cells exposed to nonapoptotic tumor cell extracts were essentially without effect. In addition, curative vaccination using APCs that had phagocytosed apoptotic bodies generated a tumor-specific cytotoxic T-cell response and long-term protection from parental tumor challenge. Thus, systems using the processing and presentation of antigenic molecules by professional APCs after phagocytosis of apoptotic bodies appear to offer new possibilities for anticancer treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416588

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

2.  Effect of bone marrow-derived monocytes transfected with RNA of mouse colon carcinoma on specific antitumor immunity.

Authors:  Xiao-Yuan Chu; Long-Bang Chen; Jing Zang; Jing-Hua Wang; Qun Zhang; Huai-Cheng Geng
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

3.  Learning from viruses: the necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong anti-tumor immune responses.

Authors:  Zhengrong Cui; Uyen M Le; Fu Qiu; Dalia S Shaker
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

Review 4.  Apoptosis and autoimmunity.

Authors:  Jeannine S Navratil; Chau-Ching Liu; Joseph M Ahearn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 5.  Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited.

Authors:  J S Navratil; J M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

6.  The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles.

Authors:  Lane Vc Black; Sarah C Saunderson; Frazer P Coutinho; Morad-Rémy Muhsin-Sharafaldine; Tanvi T Damani; Amy C Dunn; Alexander D McLellan
Journal:  Immunol Cell Biol       Date:  2015-12-09       Impact factor: 5.126

Review 7.  The cholesterol pathway: impact on immunity and cancer.

Authors:  Ryan J King; Pankaj K Singh; Kamiya Mehla
Journal:  Trends Immunol       Date:  2022-01       Impact factor: 16.687

8.  Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC.

Authors:  Eva Lion; Sébastien Anguille; Zwi N Berneman; Evelien L J M Smits; Viggo F I Van Tendeloo
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

9.  Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response.

Authors:  V Russo; S Tanzarella; P Dalerba; D Rigatti; P Rovere; A Villa; C Bordignon; C Traversari
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

10.  Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice.

Authors:  Robert E Neal; John H Rossmeisl; John L Robertson; Christopher B Arena; Erica M Davis; Ravi N Singh; Jonathan Stallings; Rafael V Davalos
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.